Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status. Top-line ...
Shares in Eli Lilly were tracking down this morning after the company revealed data on its oral weight-loss candidate, orforglipron, that seems to have once again disappointed investors. The results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback